Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Speratum Biopharma Inc. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. This prosecution activity is distributed across 2 distinct examiners but is concentrated within 1 distinct art unit. The presence of the 1 distinct art unit suggests that the company's innovations are being evaluated under a consistent departmental framework, even as they are reviewed by different individuals. This structural arrangement requires counsel to monitor procedural trends within this specific section of the patent office while managing the 2 pending office actions.
The busiest examiner for this portfolio is ELKINS, BLAKE HARRISON, who is responsible for 1 busiest_examiner_pending action. Because the total number of pending actions is 2 and the busiest examiner handles 1, the workload is divided between the 2 distinct examiners involved. Practitioners should note that this distribution prevents any single examiner from having a dominant influence over the current pending portfolio, requiring tailored strategies for each individual's preferences. Managing the workload across 2 distinct examiners within the same art unit means that while departmental guidelines remain constant, the 2 pending office actions may receive different subjective interpretations from the examiners involved in the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ELKINS, BLAKE HARRISON | 1 | 100.0% | +0.0% |
| SHIN, DANA H | 1 | 27.0% | +27.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18022263 | FLEXIBLE RNA SCAFFOLDING FOR REPROGRAMMABLE COMBINATORIAL RNAi ADMINISTRATION | SHIN, DANA H | 3d overdue |
| 18556623 | SUBSTRATE SEQUENCE DESIGN WORKFLOW FOR THE RNAI-MEDIATED MULTI-SITE REGULATION OF GENOMIC AND SUB-GENOMIC VIRAL RNAS | ELKINS, BLAKE HARRISON | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18022263 | FLEXIBLE RNA SCAFFOLDING FOR REPROGRAMMABLE COMBINATORIAL RNAi ADMINISTRATION | SHIN, DANA H | 3d overdue |
| Art Unit | Apps |
|---|---|
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18556623 | SUBSTRATE SEQUENCE DESIGN WORKFLOW FOR THE RNAI-MEDIATED MULTI-SITE REGULATION OF GENOMIC AND SUB-GENOMIC VIRAL RNAS | ELKINS, BLAKE HARRISON | — | §101§102§103§112 | Non-Final OA | — | Pending | Oct 20, 2023 |
| 18022263 | FLEXIBLE RNA SCAFFOLDING FOR REPROGRAMMABLE COMBINATORIAL RNAi ADMINISTRATION | SHIN, DANA H | 1635 | §112 | Non-Final OA | 3d overdue | Pending | Feb 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial